Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Iranian pediatric inflammatory bowel disease
IRCT20220409054467N3Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in inflammatory bowel disease (IBD), sponsored by Tehran University of Medical Sciences. Primary endpoints: Clinical activity score, Weight and 1 more. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on IRCT20220409054467N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220409054467N3.